BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34183247)

  • 1. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.
    Alhinai A; Patel K; Fonseca VA; Sebastiani G
    J Diabetes Complications; 2021 Sep; 35(9):107978. PubMed ID: 34183247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
    Makri E; Goulas A; Polyzos SA
    Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis.
    Seen TK; Sayed M; Bilal M; Reyes JV; Bhandari P; Lourdusamy V; Al-Khazraji A; Syed U; Sattar Y; Bansal R
    World J Gastroenterol; 2021 Jun; 27(23):3238-3248. PubMed ID: 34163108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
    Loomba R; Lim JK; Patton H; El-Serag HB
    Gastroenterology; 2020 May; 158(6):1822-1830. PubMed ID: 32006545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.
    Li J; Delamarre A; Wong VW; de Lédinghen V
    United European Gastroenterol J; 2024 Mar; 12(2):219-225. PubMed ID: 37987101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.
    Grecian SM; McLachlan S; Fallowfield JA; Kearns PKA; Hayes PC; Guha NI; Morling JR; Glancy S; Williamson RM; Reynolds RM; Frier BM; Zammitt NN; Price JF; Strachan MWJ
    Liver Int; 2020 Sep; 40(9):2252-2262. PubMed ID: 32638496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis.
    Tovo CV; de Mattos AZ; Coral GP; Sartori GDP; Nogueira LV; Both GT; Villela-Nogueira CA; de Mattos AA
    World J Gastroenterol; 2023 Jan; 29(2):343-356. PubMed ID: 36687125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.
    Younossi ZM
    Liver Transpl; 2018 Feb; 24(2):166-170. PubMed ID: 29272073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
    Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?
    Morrison M; Hughes HY; Naggie S; Syn WK
    Dig Dis Sci; 2019 Dec; 64(12):3394-3401. PubMed ID: 31643035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.